Home > Business > Industry

Samsung Biologics finalizes acquisition of GSK's Maryland plant

Published: 01 Apr. 2026, 13:13 Updated: 01 Apr. 2026, 13:37

KIM MIN-YOUNG
[email protected]

Attendees pose for a photo at a ceremony marking the completion of the acquisition at a biopharmaceutical production facility in Rockville, Maryland, on March 31. From fifth from left in the front row are Kang Kyung-wha, ambassador of Korea to the United States; John Rim, president and CEO of Samsung Biologics; Maryland Gov. Wes Moore; and Democratic Rep. April McClain Delaney. [SAMSUNG BIOLOGICS]

Samsung Biologics finalized the acquisition of GSK's biopharmaceutical manufacturing facility in Rockville, Maryland, securing its first production base in the United States.

The acquisition was completed on Tuesday after roughly three months of follow-up procedures from the announcement of the deal in December of last year. The acquiring entity was Samsung Biologics America, the Korean company’s U.S. subsidiary.

The Rockville facility is a 60,000-liter drug substance production plant made up of two manufacturing buildings. The site has infrastructure that can support antibody drug production at various scales, from the clinical stage to commercial manufacturing.

Through the acquisition, Samsung Biologics expanded its total production capacity from 785,000 liters (207,375 gallons) to 845,000 liters.

The company secured operational continuity of the plant by retaining all the roughly 500 local employees. Through the integration of its two production bases, the company plans to ensure a stable supply of existing products but also to step up efforts to win new orders.

John Rim, President and CEO of Samsung Biologics, delivers commemorative remarks at a ceremony marking the completion of the acquisition at a biopharmaceutical production facility in Rockville, Maryland, on March 31. [SAMSUNG BIOLOGICS]

Samsung Biologics also plans “further investments to expand the site’s capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines.”

“This represents a meaningful step in expanding our U.S. manufacturing footprint,” said John Rim, the president and CEO of Samsung Biologics. “The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family.”